New daily persistent headache (NDPH) is a chronic headache that begins suddenly in someone who doesn’t have a history of frequent headaches, then never goes away. Unlike other chronic headaches that build gradually over months or years, NDPH has a defining hallmark: you can pinpoint the exact day it started. The headache becomes unremitting from the start, or within three days of onset, and persists daily for more than three months.
NDPH is classified as a primary headache disorder, meaning it isn’t caused by another underlying condition. It affects a small fraction of the population, with estimates ranging from 0.03% to 0.1% depending on the diagnostic criteria used. But for those who develop it, the experience is often bewildering and frustrating, because the headache simply arrives one day and refuses to leave.
How NDPH Feels
The pain of NDPH typically resembles a tension-type headache: a pressing, tightening sensation on both sides of the head, mild to moderate in intensity. Some people, however, experience features more commonly associated with migraines, including throbbing pain on one side, sensitivity to light, nausea, or pain that worsens with physical activity. This overlap makes diagnosis tricky, because NDPH can look like chronic migraine on the surface.
The key difference is always the onset pattern. Chronic migraine develops from a history of episodic migraines that gradually increase in frequency. NDPH appears out of nowhere. If you can remember the specific date your headache started and it has been present nearly every day since, that pattern points toward NDPH rather than chronic migraine. People with chronic migraine also tend to have a stronger family history of headache and are more likely to experience osmophobia (an aversion to certain smells), which is uncommon in NDPH.
What Triggers the Onset
The leading trigger is a viral illness, reported in roughly 30% or more of cases. The headache typically begins during or just after the acute phase of infection and then simply persists. This pattern isn’t new. During the 1890 Russian flu pandemic, which killed one million people, physicians documented extensive neurological aftereffects, including headaches that lasted months to years after recovery. Head pain was reported in 75% to 83% of flu sufferers during the acute illness, and a subset went on to develop persistent daily headaches that matched the profile of what we now call NDPH.
Researchers have noted that the COVID-19 pandemic likely increased the number of post-viral NDPH cases, following the same pattern observed over a century earlier. Beyond infections, other reported triggers include stressful life events, surgical procedures, and illness unrelated to viruses, though many people develop NDPH with no identifiable trigger at all.
Why the Pain Persists
The exact mechanism behind NDPH remains poorly understood, which is part of what makes it so difficult to treat. The leading theory involves a process called central sensitization, where the brain’s pain-processing system becomes permanently “turned up.” Normally, pain signals diminish once a threat passes. In NDPH, the nervous system appears to get stuck in an amplified state.
One proposed driver of this process is neuroinflammation. When the brain’s immune cells, called glial cells, become activated (possibly by a viral infection or other trigger), they release inflammatory molecules that alter how pain signals are processed. These inflammatory signals can circulate in the fluid surrounding the brain and spinal cord, potentially maintaining a state of widespread pain sensitivity long after the original trigger has resolved. Brain imaging studies in people with chronic pain conditions have confirmed glial activation, supporting the idea that ongoing low-grade inflammation in the nervous system plays a role.
How It’s Diagnosed
NDPH is a diagnosis of exclusion, meaning your doctor needs to rule out other causes of daily headache before confirming it. The diagnostic workup typically includes brain imaging (usually an MRI) to check for structural problems like cysts, abnormalities at the base of the skull, or signs of conditions that mimic NDPH. One important condition to rule out is spontaneous intracranial hypotension, a cerebrospinal fluid leak that causes daily headaches and can look nearly identical to NDPH. If a leak is suspected, imaging may show characteristic brain changes, and a lumbar puncture can reveal abnormally low fluid pressure.
The formal diagnostic criteria require a headache that has been present for more than 15 days per month for at least three months, with continuous pain from onset or within three days of onset, in someone without a prior history of frequent headaches. The age of onset varies widely, from 8 to 78 years, though the average is around 32 to 36 in adults and about 14 in children and adolescents.
Treatment Options
Treating NDPH is one of the most challenging problems in headache medicine, largely because no single medication works reliably and there are no established treatment guidelines. Most approaches borrow from migraine prevention strategies, since those are the best-studied options for chronic daily headache in general.
Preventive medications commonly tried include antidepressants like amitriptyline, anticonvulsants like sodium valproate, and beta-blockers. These are typically taken daily with the goal of gradually reducing headache frequency and severity over weeks to months. Because NDPH often resembles migraine in its features, newer migraine-specific treatments have also been used. Injections that block a protein involved in migraine pain transmission (CGRP) were approved for migraine prevention and are sometimes tried for NDPH, though evidence specific to NDPH is limited.
Botulinum toxin injections, which involve multiple small injections around the head and neck every 12 weeks, have shown modest results. Roughly one-third of NDPH patients experience a meaningful reduction (30% or more) in moderate-to-severe headache days, compared to about half of chronic migraine patients. Nearly 60% of NDPH patients report some degree of subjective improvement, even when the change in headache days is small, suggesting the injections may take the edge off the pain rather than eliminate it.
For severe, treatment-resistant cases, some headache centers use aggressive inpatient protocols combining intravenous steroids, intravenous anticonvulsants, and oral antidepressants to try to break the cycle of continuous pain. In one study of 63 NDPH patients treated this way, the combination showed promise, and patients who relapsed often responded well to a second round of treatment. Anti-inflammatory medications like naproxen are sometimes added for short periods to complement other therapies.
Long-Term Outlook
NDPH has two recognized subtypes that carry very different prognoses. The self-limiting form resolves on its own, typically within several months. The refractory form resists treatment and can persist for years or even decades.
Early reports painted an optimistic picture. In the original description of NDPH, 78% of patients were pain-free without treatment within 24 months, and a later series found 66% headache-free by the same time point. However, larger and more recent studies tell a different story. In one detailed analysis, 76% of NDPH patients had continuous headache without any remission from the day it started. Only about 15% experienced complete or partial remission (defined as four or fewer headache days per month for at least three consecutive months), and another 8.5% had a relapsing-remitting pattern with periods of relief followed by return of daily headache.
Among those who do achieve remission, the timeline offers some reassurance. In the remitting group, 63% experienced their remission within 24 months. All patients in the relapsing-remitting group had their first remission within 24 months as well, with a median time to first remission of about 5.5 months. This suggests that if NDPH is going to resolve, the first two years are the most likely window. Beyond that point, the headache is more likely to be the persistent subtype, and the focus shifts from waiting for natural resolution to finding the best combination of treatments to manage pain and improve quality of life.